
11 Jan 2019 Research
Leukaemia: Investigating stem cells to prevent cancer
What is this research looking at?
The development of effective treatments to prevent and eradicate leukaemia requires a better understanding of the mechanisms behind malignant (harmful) transformation and disease persistence during therapy.
Importantly, leukaemia development is associated with the acquisition of abnormal metabolic features, making cancer metabolism an attractive target for new therapeutic strategies.
Metabolism is closely associated to cell functions in normal and abnormal (malignant) tissues. By measuring metabolic heterogeneity in normal tissue (haemopoietic stem cells) and in cancer (leukaemia), I will determine whether distinct cell metabolic states are functionally connected to their potential for malignant transformation and therapy resistance.
I will test if malignant transformation and therapy resistance can be prevented or attenuated by targeting their metabolic dependencies. Results from the proposed research may lead to the development of new strategies for leukaemia eradication and prevention.
What could this mean for people with leukaemia?
This project investigates the metabolic features of stem cells in a bid to find out how to prevent them turning cancerous and to reduce resistance to treatment – this may lead to the development of new strategies for leukaemia eradication and prevention.
Related posts
2 August 2023
Friends and family of Leicestershire woman who died from rare cancer campaign for more research and awareness
The family of a Leicestershire woman who died in July 2022, on the day of her leukaemia diagnosis, has raised over £17,000 in her memory to support Leukaemia UK. On…
15 February 2024
Vogue model who survived leukaemia as a child joins Leukaemia UK in calling for more donations for research to stop blood cancer ‘destroying childhoods’
Vogue model Saffron Vadher has joined Leukaemia UK on International Childhood Cancer Day (February 15th) in calling for more research into the blood cancer. Leukaemia is the most common type…
5 December 2022
John Goldman Fellowships for 2023 now open
Leukaemia UK is delighted to announce that we are funding more ground-breaking research in 2023, by continuing our investment in early career scientists and clinicians for our prestigious John Goldman…
28 November 2022
Leukaemia UK John Goldman Fellow awarded Professorship
Talented blood cancer researcher, Vignir Helgason, was awarded a Leukaemia UK John Goldman Fellowship in 2015, for his research into chronic myeloid leukaemia (CML). Since then, his research career has…